Archive
547 articles, sorted by publication time.
This is not a signal that AI drug development has already won, but a small step in moving a therapeutic candidate into an institutionalized development track; what will truly convince the medical community will still be subsequent experimental, toxicology, and clinical data.
Dong-A ST plans to launch the first version of its AI drug discovery platform this year. The significance is not that yet another company says it is embracing artificial intelligence, but that a traditional drugmaker is trying to bring early-stage R&D judgment, data, and risk management back into its own hands.
What is new about this collaboration is not that it is yet another AI drug development alliance, but that it reminds the market: algorithms can shorten the starting point for candidate molecules, but they cannot provide the answers to complex central nervous system biology.
A hedge fund holdings list has once again pushed AI drug discovery into the spotlight; this time, what deserves closer attention is not which companies were bought, but how much distance still needs to be genuinely closed between data, models, and experimental evidence.
Hedge fund holdings have brought AI drug discovery back into the market spotlight; but for biomedicine, capital preferences can only indicate the direction of the narrative, not replace candidate molecules, experimental validation, and clinical results.
An early trial by a Cambridge team has moved AI vaccine design from models into humans, but safety results from 39 people are only the first threshold; the real question it must answer is whether it can prepare an immune blueprint before the virus rewrites itself again.
Deepnoid’s M4CXR has received Class III medical device item approval in South Korea. The focus is not only that AI can read images, but that it is beginning to be allowed to generate preliminary reports within clinical workflows; this also brings validation standards, accountability, and the boundaries of physicians’ work closer to the forefront.
A market article using hedge fund holdings as its cue has once again pushed Tempus AI into the AI drug discovery narrative; what is really worth clarifying is that the company is not selling a single miraculous molecule, but infrastructure that connects oncology data, clinical decision-making, and R&D workflows.
A candidate drug designed by artificial intelligence has received support from South Korea’s national new drug development program, showing that AI drug discovery is moving from model demonstrations toward a more institutionalized drug development process; but public information remains limited, and the real test still lies in subsequent experimental, clinical, and regulatory evidence.
The $105 million is not merely buying a group of candidate targets, but betting on a kind of judgment: whoever can identify sooner where cancer cells are truly vulnerable may be able to rewrite the starting line for the next round of oncology drug development.
A Nature paper brings generative protein design into an urgent medical setting that has long lacked investment: if manufacturable, standardizable molecules can intercept multiple classes of snake venom toxins, antivenom treatment may not always have to remain constrained by traditional serum.
The latest market ranking has pushed AI drug discovery back to the center of the investment narrative; but capital flows can only show the heat of imagination, not replace molecular, experimental, and clinical data.